Publications

With an H-index of 75, 20612 citations, and 269 peer-reviewed publications, W Martin Kast is considered a powerhouse in immunology. All publications are available upon request.

The List

  1. McCloskey JC, Kast WM, Flexman JP, Metcalf C, French MAH and Phillips M: Syndemic synergy of HPV and other sexually transmissible pathogens in the development of high grade anal intraepithelial neoplasia. Papillomavirus Research, Submitted 2017.
  2. Mirandola L, Pedretti E, Reidy A, Chiaramonte R, Figueroa JA, Chapman C, Grizzi F, Kast WM, Cannon M, Nugyen DD, Rahman RL and Chiriva-Internati M: Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget, In Press, 2017.
  3. Garcia-Hernandez ML, Uribe-Uribe NO, Espinosa-Gonzalez R, Kast WM, Khader SA, Rangel-Moreno J: A unique cellular and molecular microenvironment is present in tertiary lymphoid organs of patients with spontaneous prostate cancer regression. Frontiers in Immunology, 8, 563, 2017. Frontiers in Immunology.
  4. Wüstenhagen E, Hampe L, Boukhallouk F, Schneider MA, Spoden GA, Negwer I, Koynov K, Kast WM, and Florin L: The cytoskeletal adaptor obscurin-like 1 interacts with the capsid protein L2 and is required for HPV16 endocytosis. J Virology, 90, 10629-10641, 2016. PubMed.
  5. Woodham AW, Sanna AM, Taylor JR, Skeate JG, Da Silva DM, Dekker LV, Kast WM. Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro. Virol J. 2016 Nov 18; 13(1):187. PubMed.
  6. Nicol AF, Brunette LL, Nuovo GJ, Grinsztejn B, Friedman RK, Veloso VG, Cunha CB, Coutinho JR, Vianna-Andrade C, Oliveira, NS, Woodham AW, Da Silva DM and Kast WM: SLPI expression and high-risk HPV infection in anal lesions of HIV patients. JAIDS, 73, 27-33, 2016, PubMed.
  7. Pulido MA, Kazarian DerHartunian M, Qin Z, Chung EM, Lee DS, Woodham AW, Tsou JA, Klooster R, Akbari O, Wang L, Kast WM, Liu SV, Verschuuren JJGM, Aswad DW and Laird-Offringa IA: Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity. J Neuroimmunology, 299, 70-78, 2016. PubMed.
  8. Da Silva DM, Woodham AW, Naylor PH, Egan JE, Berinstein NL and Kast WM. Immunostimulatory activity of the cytokine-based biologic IRX-2 on Human Papillomavirus-exposed Langerhans cells. J Interferon & Cytokine Res. 36:291-301, 2016. PubMed.
  9. Woodham AW, Skeate JG, Sanna AM, Taylor JT, Da Silva DM, Cannon PM, Kast WM. HIV immune cell receptors, coreceptors, and cofactors: Implications for prevention and treatment. AIDS Patient Care and STDs. PubMed.
  10. Woodham AW, Yan L, Skeate JG, van der Veen D, Brand HE, Wong MK, Da Silva DM, Kast WM. T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation. Papillomavirus Research. Science Direct.
  11. Skeate JG, Woodham AW, Einstein MH, Da Silva DM, Kast WM. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Human Vaccines & Immunotherapeutics. Taylor and Francis Online.
  12. Da Silva DM, Woodham AW, Naylor PH, Egan JE, Berinstein NL, Kast WM. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. Journal of Interferon & Cytokine Research. PubMed.
  13. Skeate JG, Porras TB, Woodham AW, Jang JK, Taylor JR, Brand HE, Kelly TJ, Jung JU, Da Silva DM, Weiming Y, Kast WM. Herpes Simplex Virus downregulation of secretory leukocyte protease inhibitor enhances Human Papillomavirus type 16 infection. Journal of General Virology. PubMed.
  14. Da Silva DM, Woodham AW, Skeate JG, Rijkee LK, Taylor JR, Brand HE, Muderspach LA, Roman LA, Yessaian AR, Pham H, Matsuo K, Linn Y, McKee GM, Salazar AM, Kast WM. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Journal of Clinical Immunology. ScienceDirect.
  15. Bogaert L, Woodham AW, Da Silva DM, Martens A, Meyer E, Kast WM. A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumors. Journal of General Virology. PubMed.
  16. Da Silva DM, Woodham AW, Rijkee LK, Skeate JG, Taylor JR, Koopman ME, Brand HE, Wong M, McKee GM, Salazar AM, Kast WM. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly I:C. PVR. ScienceDirect.
  17. Woodham AW, Taylor JR, Jimenez, AI, Skeate JG, Schmidt T, Brand HE, Da Silva DM, and Kast WM. Annexin A2 heterotetramer small molecule inhibitors prevent human papillomavirus type 16 infection. Journal of Antimicrobial Chemotherapy. PubMed.
  18. Woodham AW, Raff AB, Da Silva DM, Kast WM: Molecular analysis of human papillomavirus virus-like particle activated langerhans cells in vitro. Methods Mol Biol. 2015;1249:135-49. PubMed
  19. Yan L, Woodham AW, Da Silva DM, Kast WM: Functional Analysis of HPV-Like Particle-Activated Langerhans Cells In Vitro. Methods Mol Biol. 2015; 1249:333-50. PubMed
  20. Hu JS, Skeate JG, Kast WM, Wong MK: Immunotherapy in Sarcoma: A Brief Review. Sarcoma Research – International, 1:1-8, 2014. Sarcoma Research – International
  21. Yan L, Da Silva DM, Verma B, Gray A, Brand HE, Skeate JG, Porras TB, Kanodia S, and Kast WM: Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. The Prostate. 2014. PubMed
  22. Woodham AW, Raff AB, Raff LM, Da Silva DM, Yan L, Skeate JG, Wong MK, Lin YG and Kast WM: Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunology, 192:4748-4757, 2014. PubMed
  23. Da Silva DM, Movius CA, Raff AB, Brand HE, Skeate JG, Wong MK and Kast WM: Suppression of Langerhans cell activation is conserved amongst human papillomavirus alpha and beta genotypes but not in a mu genotype. Virology, 452–453:279–286, 2014. PubMed
  24. Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva DM, Schelhaas M and Kast WM: The evolving field of human papillomavirus receptor research: a review of binding and entry, J Virol, 87(11):6062-6072, 2013. PubMed
  25. Hoffmann M, Pfannenschmidt S, Hebebrand L, Görögh T, Halec G, Kahn T, Quabius ES, Tribius S, Ihloff AS, Röcken C, Haag J, Waterboer T, Schmitt M, Guliani A and Kast WM: The role of secretory leukocyte protease inhibitor in HPV infected head and neck cancer. Oncology Reports, 5:1962-1968, 2013. PubMed
  26. Bot A, Ahn M, Bosch M, Brostedt D, Butterfield L, Cornforth A, Harrop R, Kast WM, Koya R, Marincola F, Margolin K, McCoy C, Pawelec G, Rothman J, Schlom J, Srivastava P, Wallis S, Walter S, Wang E, Waslif J: A Novel Series of Conferences Tackling the Hurdles Confronting the Translation of Novel Cancer Immunotherapies, J Transl Med 10:218, 2012. PubMed
  27. Pandey A, Kurup A, Shrivastava A, Radhi S, Nguyen DD, Arentz C, D’Chuna N, Hardwick F, D’Souza MJ, Jenkins M, Grizzi F, Kast WM, Cobos E, Rahman R, Chiriva-Internati M, Chiaramonte R, Platonova N: Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol 31: 302-320, 2012. PubMed
  28. Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, Brand HE, Isas JM, Langen R, Kast WM: The S100A10 subunit of the Annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS ONE, 7: e43519, 2012. PubMed
  29. Kanodia S, Da Silva DM, and Kast WM: Recent Advances in strategies for immunotherapy of human papillomavirus-induced lesions. Austral-Asian J Cancer, 11:143-162, 2012.
  30. Mirandola L, Chiriva-Internati M, Montagna D, Locatelli F, Zecca M, Ranzani M, Basile A, Locati M, Cobos E, Kast WM, Comi P and Chiaramonte R: Notch1 regulates chemotaxis and proliferation by controlling the chemokine receptors 5 and 9 in T-cell acute lymphoblastic leukemia. J Pathol, 226:713-722, 2012. PubMed
  31. Jenkins M, Chiriva-Internati M, Mirandola L, Tonroy C, TedjaratI SS, Davis N, Kast WM and Cobos E: Perspective for Prophylaxis and Treatment of Cervical Cancer: an Immunological Approach. Int Rev Immunol 31:3-21, 2012. PubMed
  32. Schutt C, Bumm K, Mirandola L, Jenkins M, Cobos E, Joseph C, Kast WM, Chiriva-Internati M: A comprehensive review of treatment options for squamous cell carcinoma of the head and neck: Why immunotherapy may hold the key. Int Rev Immunol. 31:22-42, 2012.
  33. Chiriva-Internati M, Kast WM and Bot A: Targeting HPV-Associated disease, from cervical to head and neck carcinoma…and more. Int Rev Immunol, 31:1-2, 2012. PubMed
  34. Chiriva-Internati M, Yu Y, Mirandola, L, D’Cunha N, Hardwicke F, Cannon, MJ, Cobos E and Kast WM: Identification of AKAP-4 as a new cancer testis antigen for detection and immunotherapy of prostate cancer. Prostate, 72: 12-23, 2012. PubMed
  35. Mirandola L, Comi P, Cobos E, Kast WM, Chiaramonte R and Chiriva-Internati M: Notch-ing from T Cell Leukemia to Multiple Myeloma, Cancer Letters, 308, 1-13 2011.
  36. Chiriva-Internati M, Yu Y, Kelly A, Jenkins M, Gornati R, Bernardini G, Kast WM and Cobos E: Ropporin: a novel cancer testis antigen for multiple myeloma immunotherapy. J Immunother, 34: 490-499, 2011. PubMed
  37. Mirandolo L, Cannon, M, Cobos E, Bernardini G, Jenkins MR, Kast WM and Chiriva-Internati M: Cancer Testis Antigens: Novel Biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol. 30:127-37, 2011. PMID: 21557639
  38. Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E and Cannon MJ: Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol, 30; 71-86, 2011. PMID: 21557635
  39. Cordes C, Hasler R, Werner C, Goroch T, Rocken C, Hebebrand L, Kast WM, Hoffmann M, Schreiber S and Ambrosch P: The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol, 39: 185-191, 2011. PMID:21503571
  40. Bogaert L, Martens A, Kast WM, Van Marck E and De Cock H: Bovine papillomavirus DNA can be detected in keratinocytes from equine sarcoids. Vet Microbiol, 146: 269-275, 2010. PMID: 21095508
  41. Gray A, Yan L and Kast WM: Prevention is better than cure: The case for clinical trials of therapeutic cancer vaccines in the prophylactic setting. Mol Interventions, 10: 197-203, 2010. PMID: 20729485
  42. Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon MJ, Cobos E and Kast WM: Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS ONE, 5:e10471, 2010. PMID: 20485677
  43. Kanodia S, Da Silva DM, Karamanukyan T, Bogaert L, Fu YX and Kast WM: Expression of LIGHT/NFSF14 combined with vaccination against HPV16 E6 and E7 induces significant tumor regression. Cancer Research, 70: 3955-3964, 2010. PMID: 20460520
  44. Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA and Sondak VK: Phase II trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer, 116:424-431, 2010. PMID 19918923
  45. Gray A, Garcia-Hernandez ML, Van West M, Kanodia S, Hubby B, and Kast WM: Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine, 27S: G52-G59, 2009. PMID: 20006141
  46. Fahey LM, Raff AB, Da Silva DM, and Kast WM: A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol, 183: 5151-5156, 2009*. PMID: 19864613, PMCID: 2947488
  47. Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D’Souza G, Gravitt PE, Westra W, Psyrri A, Kast WM, Koutsky LA, Giuliano A, Krosnick S, Trotti A, Schuller DE, Forastiere A, and Ullmann CD: Squamous Cell Head and Neck Cancer and Human Papillomavirus. Head and Neck, 31: 1393-1422, 2009. PMID: 19787782
  48. Smith KA, Meisenburg BL, Tam VL, Pagarian RR, Wong R, Joea DK, Lantzy L, Carrillo MA, Gross T, Malyankar UM, Chiang C-S, Da Silva DM, Kundig TM, Kast WM, Qiu Z and Bot A: Lymph node targeted immunotherapy mediates potent immunity resulting in regression of isolated or disseminated HPV transformed tumors. Clin Cancer Res, 15: 6167-6176, 2009. PMID: 19789304
  49. Chiriva-Internati M, Gagliano N, Donetti E, Gioia M, Jenkins M, Cobos E and Kast WM: Sperm protein 17 is expressed in the sperm fibrous sheath. J Transl Med, 7: 61, 2009. PMID: 19604394
  50. Hitzeroth II, Passmore JS, Shepherd E, , Stewart D, Mueller M, Williamson A, Rybicki EP and Kast WM: Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine, 27: 6432-6434, 2009. PMID: 19559114
  51. Leffers N, Gooden MJM, Mokhova AA, Kast WM, Neefjes JJ, ten Hoor KA, Hollema H, Daemen T, van der Zee AGJ and Nijman HW: Downregulation of proteasome subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gyn Onc, 113: 256-263, 2009. PMID: 19243813
  52. Fahey LM, Raff A, Da Silva DM, and Kast WM: Reversal of HPV-specific T cell immune suppression through TLR8 agonist treatment of LC exposed to HPV 16. J Immunol, 182:2919-2928, 2009. PMID: 19234187
  53. Koh YT, Gray A, Higgins SA, Hubby B and Kast WM: Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate, 69: 571-584, 2009. PMID: 19143030
  54. Yu Y, Pilgrim P, Zhou W, Gagliano N, Frezza EE, Jenkins M, Weidanz JA, Lustgarten J, Cannon M, Bumm K, Cobos E, Kast WM and Chiriva-Internati M: rAAV/Her-2/neu loading of DC for a potent cellular mediated MHC I restricted immune response against ovarian cancer. Viral Immunology, 21: 435-442, 2008. PMID: 19115932
  55. Kanodia S and Kast WM: Peptide-based vaccines for cancer: realizing their potential. Exp Rev Vac, 7: 1533-1545, 2008. PMID: 19053209
  56. Raff AB, Gray A and Kast WM: Prostate Stem Cell Antigen: A prospective therapeutic and diagnostic target. Cancer Letters, 277: 126-132, 2009*. PMID: 18838214
  57. Moore TV, Lyons GE, Brasic N, Roszkowski JJ, Voelkl S, Mackensen A, Kast WM, Le Poole IC and Nishimura MI: Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother, 58:719-728, 2009. PMID: 18836717
  58. Yu Y, Pilgrim P, Yan J, Zhou W, Jenkins M, Gagliano N, Bumm K, Cannon M, Milzani A, Dalle-Donne I, Kast WM, Cobos E, and Chiriva-Internati M: Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med, 6:56, 2008. PMID: 18834548
  59. Chiriva-Internati M, Weidanz J, Raffaele F, Yu Y, Frezza E, Jenkins M, Cobos E, Kast WM: Sp17 is a suitable target for adoptive T-cell therapy in human ovarian cancer. J Immunother, 31: 693-703, 2008. PMID: 18779750
  60. Song LL, Peng Y, Yun J, Rizzo P, Chaturvedi V, Weijzen S, Kast WM, Stone PJ, Santos L, Loredo A, Lendahl U, Sonenshein G, Osborne B, Qin JZ, Pannuti A, Nickoloff BJ and Miele L: Notch-1 associates with IKKa and regulates IKK activity in cervical cancer cells. Oncogene, 27:5833-5844, 2008. PMID: 18560356
  61. Chiriva-Internati M, Cobos E, Da Silva DM and Kast WM: Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun, 8:8, 2008. PMID: 18433090
  62. Chiriva-Internati M, Ferrari R, Prabhakar M, Yu Y, Baglioni L, Moreno J, Gagliano N, Portinaro N, Jenkins MR, Frezza E, Hardwicke F, D’Cunha N, Kast WM and Cobos E: PTTG-1: An immunological target for multiple myeloma. J Trans Med, 6:15, 2008. PMID: 18384692
  63. Garcia-Hernandez ML, Gray A, Klinger OJ, Hubby B and Kast WM: PSCA vaccination induces a longterm prostate cancer protective immune response in the absence of autoimmunity. Cancer Res, 68: 861-869, 2008*. PMID: 18245488
  64. Gray A, Raff AB, Chiriva-Internati M, Chen SY and Kast WM: A paradigm shift in therapeutic vaccination: the need to apply therapeutic vaccines in the preventive setting. Immunol Rev, 222: 316-327, 2008. PMID: 18364011
  65. Le Poole IC, ElMasri W, Denman C, Kroll TM, Bommiasamy H, Lyons GE and Kast WM: Cytotoxicity of DC and LC towards epithelial cells expressing HPV 16 E6 and E7. Cancer Immunol Immunother, 57:789-797, 2008. PMID: 18004565
  66. Chiriva-Internati M, Ferrari R, Yu Y, Hamrick C, Grizzi F, Frezza E, Jenkins M, Hardwick F, D’Cunha N, Kast WM, Cobos E: AKAP-4: a novel Cancer Testis Ag for Multiple Myeloma. Brit J Haematol, 140: 465-468, 2008.
  67. Kanodia S, Da Silva DM, and Kast WM: Recent Advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer, 122:247-259, 2008. PMID: 17973257
  68. Janetzki S, Panageas K, Ben-Porath L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM and Hoos A: Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium: Cancer Immunol Immunother, 57: 303-315, 2008.* PMID: 17721781
  69. Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM and Weber JS: PD-1 blockade enhances expansion and functional capacity of human melanoma ag specific CTLs. Int Immunol. 19:1223-1234, 2007.
  70. Roman, LD, Wilczynski S, Muderspach LI, Burnett AF, O’Meara, A, Brinkman JA, Kast WM, Facio G, Felix J, Aldana M and Weber JS: A phase II study of Hsp-7 in women with high grade cervical dysplasia. Gyn Onc, 106: 558-566, 2007. PMID: 17631950
  71. Chiriva-Internati M, Cobos E and Kast WM: Advances in immunotherapy of Multiple Myeloma: From the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol, 26:197-222, 2007.
  72. Garcia-Hernandez ML, Gray A, Hubby B and Kast WM: In vivo effects of vaccination with Steap: a candidate antigen for treating prostate cancer. Cancer Res, 67: 1344-1351, 2007*. PMID: 17283172
  73. Da Silva DM, Fausch SC, Verbeek SJ and Kast WM: Uptake of HPV virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity, J Immunol, 178: 7587-7597, 2007. PMID: 17548594
  74. Daftarian P, Mansour M, Pohajdak B, Fuentes-Ortega A, Korets-Smith E, Brown, RG and Kast WM: Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J Trans Med, 5: 26, 2007. PMID: 17555571
  75. Mansour M, Pohajdak B, Kast WM, Fuentes-Ortega A, Korets-Smith E, Weir G, Brown RG and Daftarian P: Therapy of B16-F10 melanoma tumors by a single vaccination of CTL/Thelper peptides in VacciMax. J Transl Med, 5:20, 2007.
  76. Lambeck AJA, Grijns APG, Leffers N, Sluiter WF, ten Hoor KA, Braid M, van der Zee AGJ, Daemen T, Nijman HW and Kast WM: Cytokine profiling as diagnostic and prognostic marker in ovarian cancer: a potential role for IL-7. Clin Cancer Res, 13: 2385-2391, 2007. PMID: 17438097
  77. Chiriva-Internati M, Grizzi F, Weidanz JA, Ferrari R, Yuefei Y, Velez B, Shearer MH, Lowe DB, Frezza E, Cobos E, Kast WM and Kennedy RC: A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Meth, 321: 86-93, 2007.
  78. Brinkman JA, Xu X and Kast WM: The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV 16 induced tumors. Vaccine, 25: 3437-3444, 2007. PMID: 17241713
  79. Brinkman JA, Hughes SH, Stone P, Caffrey AS, Muderspach LI, Roman LD, Weber JS and Kast WM: Therapeutic vaccination for HPV induced cervical cancers. Dis Markers, 23:337-352, 2007. PMID: 17627067
  80. Kanodia S, Fahey LM and Kast WM: Mechanisms used by human papillomavirus to escape the host immune response. Curr Cancer Drug Targets, 7: 79-89, 2007. PMID: 17305480
  81. Koh YT, Higgins SA, Weber JS and Kast WM: Comparison of immune responses induced by peptide based vaccines emulsified through three different techniques in incomplete Freund’s adjuvant. J Transl Med, 4:42, 2006. PMID: 17059610
  82. Daftarian P, Pohajdak B, Benoit AC, Mansour M, Hoskin DW, Brown RG and Kast WM: Eradication of HPV16-expressing established tumors by a single administration of a vaccine of a liposome-encapsulated CTL-T helper fusion peptide in a water in oil emulsion. Vaccine, 24: 5235-5244, 2006*.
  83. Chiriva-Internati M, Grizzi F, Pinkston J, Morrow KJ, D’Cunha ND, Frezza EE, Muzzio PC, Kast WM and Cobos E: Gamma-radiation up-regulates MHC Class I/II and ICAM-I molecules in Multiple Myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim, 42: 89-95, 2006.
  84. Lyons GE, Roszkowski JJ, Man S, Yee C, Kast WM and Nishimura MI: TCR tetramer binding or the lack there of does not necessitate antigen recognition in TCR transduced T cells. Cancer Immunol Immunother, 55:1142-1150, 2006.
  85. Bumm K, Grizzi F, Franceschini B, Koch M, Iro H, Wurm J, Ceva-Grimaldi G, Dimmler A, Cobos E, Dioguardi N, Sinha UK, Kast WM, and Chiriva-Internati M: Sperm protein 17 expression defines two subsets of primary esthesioneuro­blastoma. Hum Pathol, 36: 1289-1293, 2005.
  86. Da Silva D, Kast WM: Vaccination against cervical cancer: hopes and realities. Am J Cancer, 4:207-219, 2005.
  87. Warrino DE, Olson WC, Scarrow MI, D’Ambrosio-Brennan LJ, Guido RS, Da Silva DM, Kast WM and Storkus WJ: HPV L1L2-E7 virus-like particles (VLPs) partially mature human DCs and elicit specific T-helper responses from a high frequency of patients with CIN or cervical cancer in vitro. Hum Immunol, 66: 762-772, 2005. PMID: 16112023
  88. Fausch SC, Fahey LM, Da Silva DM and Kast WM: HPV can escape immune recognition through Langerhans cell PI3-kinase activation, J Immunol, 174:7172-7178, 2005. PMID: 15905561
  89. Brinkman JA, Caffrey A, Muderspach L, Roman L and Kast WM: The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: Consequences for clin. management. Eur J Gyn Onc, 26:129-142, 2005.
  90. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K and Nishimura MI: Simultaneous generation of CD8+ and CD4+ melanoma reactive T cells by retroviral mediated transfer of a single TCR. Cancer Res, 65:1570-1576, 2005.
  91. Fausch SC, Da Silva DM and Kast WM: Heterologous Papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine, 23:1720-1729, 2005. PMID: 15705478
  92. Harrison J and Kast WM: Cure of glioma: a space not yet occupied for the lesion. Can Inv, 22:479-480, 2004.
  93. Markiewicz MA and Kast WM: Progress in the development of immunotherapy of cancer using ex vivo generated DC expressing multiple tumor antigen epitopes. Cancer Invest, 22:417-434, 2004. PMID: 15493363
  94. Chiriva-Internati M, Grizzi F, Bright RK and Kast WM: Cancer Immunotherapy: Avoiding the road to perdition. J Transl Med, 2:26, 2004.
  95. Kast WM, Levitsky H and Marincola FM: Synopsis of the 6th Walker’s Cay Colloquium on Cancer Vaccines and Immunotherapy. J Transl Med, 2:20, 2004.
  96. Warrino DE, Olson WC, Knapp WT, Scarrow MI, Brennan LJ, Guido RS, Edwards RP, Kast WM, and Storkus WJ: Disease-stage variance in functional CD4+ T cell responses against novel Pan-HLA-DR presented HPV-16 E7 epitopes. Clin Cancer Res, 10:3301-3308, 2004.
  97. Schreiber K, Cannon RE, Karrison T, Beck-Engeser G, Huo D, Tennant RW, Jensen H, Kast WM, Krausz T, Meredith SC, Chen L, and Schreiber H: Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene, 23:3972-3979, 2004.
  98. Grizzi F, Chiriva-Internati M, Franceschini B, Bumm K, Colombo P, Ciccarelli M, Donetti E, Gagliano N, Hermonat PL, Bright RK, Gioia M, Dioguardi N and Kast WM: Sperm Protein 17 is expressed in somatic ciliated epithelia. J Histochem Cytochem, 52:549-554, 2004.
  99. Brinkman JA, Fausch SC, Weber JS and Kast WM: Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther, 4:181-198, 2004. PMID: 14998777
  100. Cassetti MC, McElhiney SP, Shahabi V, Pullen JK, Le Poole IC, Eiben GL, Smith LR and Kast WM: Antitumor efficacy of VEEV Replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine, 22:520-527, 2004. PMID: 14670335
  101. Wilcox RA, Tamada K, Flies DB, Zhu G, Chapoval AI, Blazer BR, Kast WM, and Chen L: Ligation of CD137 receptor prevents and reverses established anergy of CD 8+ CTL in vivo. Blood, 103:177-184, 2004.
  102. Brinkman JA, Caffrey A, Muderspach L, Roman L and Kast WM: The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: Consequences for clin. management. CME J Gyn Onc, 9: 217-230, 2003.
  103. Mitchell MS and Kast WM: Synopsis of the 5th Annual Cancer Vaccines and Immunotherapy Colloquium at Walker’s Cay. Cancer Immunol Immunother, 52:655-660, 2003.
  104. Chiriva Internati M, Grizzi F, Hermonat P and Kast WM: Is sperm protein 17 a useful target for tumor immunotherapy? Blood, 102:2308-2309, 2003.
  105. Le Poole IC, Bommiasamy H, Bocchetta M and Kast WM: Advances in prophylactic cancer vaccine research. Expert Rev Anticancer Ther, 3:537-545, 2003.
  106. Fausch SC, Da Silva DM and Kast WM: Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res, Advances in Brief, 63:3478-3482, 2003. PMID: 12839929
  107. Da Silva DM, Schiller JT and Kast WM: Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine, 21:3219-3227, 2003. PMID: 12804851
  108. Le Poole IC, Bommiasamy H and Kast WM: Recent progress in tumor vaccine development. Expert Opin Invest Drugs, 12:971-981, 2003.
  109. Eiben GL, Da Silva DM, Fausch SC, Le Poole IC, Nishimura MI and Kast WM: Cervical Cancer Vaccines: Recent advances in HPV research. Viral Immunol, 16:111-121, 2003. PMID: 12828864
  110. Kotecha MT, Afghan RK, Vasilikopoulou E, Wilson E, Marsh P, Kast WM, Davies DH and Caparros-Wanderley W: Enhanced tumor growth after DNA vaccination against human papillomavirus E7 oncoprotein: evidence for tumor-induced immune deviation. Vaccine, 21:2605-2615, 2003.
  111. Velders MP, Markiewicz MA, Eiben GL and Kast WM: CD4 T cell matters in tumor immunity. Int Rev Immunol, 22:113-140, 2003. PMID: 12962272
  112. Mitchell MS and Kast WM: The Albert B. Sabin Vaccine Institute 4th Annual Colloquium on Cancer Vaccines and Immunotherapy. Cancer Immunol Immunother, 52:1-38, 2003.
  113. Weijzen S, Zlobin A, Braid M, Miele L and Kast WM: HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J. Cell Physiol, 194:356-362, 2003. PMID: 12548555
  114. Fausch SC, Da Silva DM, Eiben GL, Van Kasteren RP, Le Poole IC and Kast WM: HPV peptide/protein based vaccines: From animal models to clinical trials. Front. Biosci, 8:81-91, 2003. PMID: 12456298
  115. Markiewicz MA and Kast WM: Advances in immunotherapy for prostate cancer. Adv Cancer Res, 87:159-194, 2003. PMID: 12641276
  116. Wakabayashi MT, Da Silva DM, Potkul R and Kast WM: Comparison of HPV16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology,45:300-307, 2002. PMID: 12566713
  117. Villa LL, Bernard H-U, Kast WM, Hildesheim A, Amestoy G and Franco EL: Past, present, and future of HPV research: Highlights from the 19th Int. Papillomavirus Conference-HPV 2001. Virus Res, 89:163-73, 2002.
  118. Mitchell MS and Kast WM: Synopsis of 4th Walker’s Cay Meeting on cancer vaccines, 7-10 March, 2002. Cancer Immunol Immunother, 51:674-676, 2002.
  119. Eiben GL, Velders MP, Schreiber H, Cassetti MC, Pullen JK, Smith L, and Kast WM: Establishment of an HLA-A*0201 HPV 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res, 62:5792-5799, 2002.* PMID: 12384540
  120. Le Poole IC, Gerberi M, Kast WM: Emerging strategies in tumor vaccines. Curr Opin Onc, 14:641-648, 2002.
  121. Weijzen S, Velders MP, Elmishad AG, Bacon PE, Panella JR, Nickoloff BJ, Miele L and Kast WM: The notch ligand jagged-1 is able to induce maturation of monocyte-derived human DC. J Immunol, 169:4273-4278, 2002. PMID: 12370358
  122. Fausch SC, Da Silva DM, Rudolf MP and Kast WM: HPV VLP do not activate Langerhans cells: A possible immune escape mechanism used by HPV. J Immunol, 169:3242-3249, 2002.* PMID: 12218143
  123. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne B, Gottipati S, Aster JC, Hahn WC, Rudolf MP, Siziopikou K, Kast WM and Miele L: Activation of Notch-1 signalling maintains the neoplastic phenotype in Ras-transformed cells. Nature Medicine, 8:979-986, 2002.* PMID: 12185362
  124. Schreiber H, Wu T, Nachman J and Kast WM: Immunodominance and tumor escape. Semin Cancer Biol, 12:25-31, 2002.
  125. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A and Atkins MB: Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the SBT. J Immunother, 25:97-138, 2002.
  126. Eiben GL, Velders MP and Kast WM: The cell mediated immune response against HPV induced cervical cancer: implications for immunotherapy. Adv Cancer Res. 86:113-148, 2002. PMID: 12374277
  127. Salit RB, Kast WM and Velders MP: The ins and outs of clinical trials with peptide based vaccines. Front. Biosci, 7:e204-213, 2002. PMID: 11991853
  128. Le Poole IC, Riker AI, Quevedo M, Stennett L, Wang E, Marincola FM, Kast WM, Robinson JK, and Nickoloff BJ: IFNg reduces melanosomal antigen expression and recognition of melanoma cells by CTL. Am J Pathol, 160: 521-528, 2002.
  129. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM and Kwon ED: T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci, 98:14565-14570, 2001. PMID: 11734652
  130. Da Silva DM, Pastrana DV, Schiller JT and Kast WM: Effects of pre-existing neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology, 290:350-360, 2001.
  131. Velders MP, McElhiney S, Cassetti MC, Eiben GL, Higgins T, Kovacs GR, Elmishad AG, Smith L, and Kast WM: Eradication of established tumors by vaccination with VRP delivering HPV16E7 RNA. Cancer Res, 61:7861-7867, 2001.
  132. Yang D, Holt GE, Velders MP, Kwon ED and Kast WM: Murine steap, Psca and Psma: Prostate-specific cell-surface antigens highly expressed in prostate cancer of TRAMP mice. Cancer Res, 61:5857-5860, 2001. PMID: 11479226
  133. Heller JD, Kuo J, Wu TC, Kast WM, and Huang RC: Tetra-O-methyl Nordihydroguaiaretic Acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo. Cancer Res, 61:5499-5504, 2001.
  134. Velders MP, Macedo M, Provenzano M, Elmishad A, Holzhütter HG, Carbone M, and Kast WM: Human T cell responses to endogenously presented HLA-A2 restricted SV40T peptides. J Cell Biochem, 82:155-162, 2001.
  135. Powers A, Rizzo P, Di Resta I, Matker CM, Kast WM, Mutti L, Pass HI and Carbone M: SV40, Asbestos, and the development of malignant mesotheliomas. Can Mineral, 5:135-140, 2001.
  136. Weijzen S, Meredith SC, Velders MP, Elmishad AG, Schreiber H and Kast WM: Pharmacokinetic differences between a T cell tolerizing peptide and a T cell activating peptide. J Immunol, 166:7151-7157, 2001. PMID: 11390461
  137. Velders MP, Ter Horst SAJ, and Kast WM: Prospects for immunotherapy of acute lymphoblastic leukemia. Leukemia, 15:701-706, 2001. PMID: 11368429
  138. Rudolf MP, Fausch SC, Da Silva DM, and Kast WM:   Human DC are activated by chimeric human papillomavirus type-16 VLP and induce epitope specific human T-cell responses in vitro. J Immunol, 166:5917-5924, 2001.* PMID: 11342606
  139. Gabrilovich DI, Velders MP, Sotomayor E, and Kast WM: Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol, 166:5398-5406, 2001. PMID: 11313376
  140. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L and Kast WM: Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol, 166:5366-5373, 2001.* PMID: 11313372
  141. Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, and Kast WM: Physical interaction of human papillomavirus virus-like particles with immune cells. Int Immunol, 13:633-641, 2001.* PMID: 11312251
  142. Small LA, Da Silva DM, De Visser KE, Velders MP, Fisher SG, Potkul RK and Kast WM: A murine model for the effects of pelvic radiation and cisplatin chemotherapy on HPV vaccine efficacy. Clin Cancer Res, 7:876-881, 2001.
  143. Schreiber K, Wu T, Kast WM and Schreiber H. Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res, 7:871-875, 2001.
  144. Rudolf MP, Man S, Melief CJM, Sette A, and Kast WM: Human T-cell responses to HLA-A restricted high affinity binding peptides of HPV-18 proteins E6 and E7. Clin Cancer Res, 7:788-795, 2001.* PMID: 11300474
  145. Da Silva DM, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, Velders MP, and Kast WM: Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol, 186:169-182, 2001. PMID: 11169454
  146. Revaz V, Benyacoub J, Kast WM, Schiller JT, De Grandi P and Nardelli-Haefliger D. Mucosal vaccination with a recombinant S. Typhimurium expressing HPV16 L1 VLPs or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology, 279: 354-360, 2001.
  147. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V and Weber J: A phase I trial of a HPV peptide vaccine for women with high grade cervical and vulvar intraepithelial neoplasia who are HPV16 positive. Clin Cancer Res, 6:3406-3416, 2000.
  148. Jang MS, Zlobin A, Kast WM and Miele L: Notch signalling as a target in multimodality cancer therapy. Curr Opin Mol Ther 2:55-65, 2000.
  149. Ressing ME, Van Driel WJ, Brandt RMP, Kenter GG, De Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM and Melief CJM: Detection of T-helper responses, but not of HPV-specific CTL responses, following peptide vaccination of cervical carcinoma patients. J Immunother 23:255-266, 2000.
  150. Kast WM, Schreiber H and Velders MP: Tumour immunology. In: Encyclopedia of Life Sciences. Wiley Interscience, http://els.wiley.com/els/public/home/default.asp?sessionid=public1-10, 1999.
  151. Schurmans LRHM, Den Boer ATh, Diehl L, Van der Voort EIH, Kast WM, Melief CJM, Toes REM and Jager MJ: Successful immunotherapy of an intraocular tumor. Cancer Res 59:5250-5254, 1999.
  152. Street M, Herd K, Londono P, Doan T, Dougan G, Kast WM and Tindle RW: Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the HBV core antigen (HBcAg) c/e1-region. Arch Virol 144:1323-1343, 1999.
  153. De Visser KE and Kast WM: Effects of TGF-b on the immune system; implications for cancer immunotherapy. Leukemia 13:1188-1199, 1999.
  154. Van Driel WJ, Ressing ME, Kenter GG, Brandt RMP, Krul EJ, Van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, Van Dam PA, Fleuren GJ, Kast WM, Melief CJM, Trimbos JB: Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35:946-952, 1999.
  155. Ressing ME, De Jong JH, Brandt RMP, Drijfhout JW, Benckhuijsen WE, Schreuder GMT, Offringa R, Kast WM and Melief CJM: Differential binding of viral peptides to HLA-A2 alleles. Implications for HPV16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol 29:1292-1303, 1999.
  156. Weijzen S, Velders MP and Kast WM: Modulation of the immune response and tumor growth by activated Ras. Leukemia 13:502-513, 1999. PMID: 10214854
  157. Nieland JD, Da Silva DM, Velders MP, De Visser KE, Schiller JT, Müller M and Kast WM: Chimeric HPV VLP induce a murine self-antigen-specific therapeutic antitumor response. J Cell Biochem 73:145-152, 1999.* PMID: 1022737
  158. Rudolf MP, Nieland JD, Da Silva DM, Velders MP, Müller M, Greenstone HL, Schiller JT and Kast WM: Induction of HPV16 capsid protein specific human T-cell responses by VLP. Biol Chem 380:335-340, 1999. PMID: 10223336
  159. Da Silva DM, Velders MP, Rudolf MP, Schiller JT, Kast WM: Papillomavirus virus-like particles as anticancer vaccines. Curr Opin Mol Ther 1:82-88, 1999. PMID: 11249689
  160. De Bruijn MLH, Greenstone HL, Vermeulen H, Melief CJM, Lowy DR, Schiller JT and Kast WM: L1 specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250:371-376, 1998.
  161. Kast WM: Infection, Immunity and Cancer. Invest Drugs 41:41-44, 1998.
  162. Vierboom MPM, Feltkamp MCW, Neisig A, Drijfhout JW, Ter Schegget J. Neefjes JJ, Melief CJM and Kast WM: Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild type epitope. J Immunother 21:399-408, 1998.
  163. Rizzo P, Di Resta I, Stach R, Mutti L, Picci P, Kast WM, Pass HI and Carbone M: Evidence for and implications of SV40 sequences in human mesothelioma and osteosarcoma. Dev Biol Stand 94:33-40, 1998.
  164. Velders MP, Schreiber H and Kast WM: Active immunization against cancer cells: impediments and advances. Semin Onc 25:697-706, 1998. PMID: 9865683
  165. Nieland JD, Loviscek K, Kono K, Albain KS, McCall AR, Potkul RK, Fisher SG, Velders MP, Petersson M, Kiessling R, Kast WM: PBL of early breast carcinoma patients with a high nuclear grade tumor unlike PBL of cervical carcinoma patients do not show a decreased TCR expression but are functionally impaired. J Immunother 21:317-322, 1998.
  166. Macedo MF, Velders MP, Nieland JD, Rudolf MP, Weijzen S, Da Silva DM, Franke A, Holt GE, Loviscek K, Carbone M and Kast WM: Cellular Immunity and Immunotherapy Against DNA Virus Induced Tumors. Monaldi Arch Chest Dis 53:211-218, 1998. PMID: 9689811
  167. Rizzo P, Di Resta I, Powers A, Matker CM, Zhang A, Mutti L, Kast WM, Pass H and Carbone M: The detection of SV40 in human tumors by PCR. Monaldi Arch Chest Dis, 53:202-210, 1998.
  168. Matker CM, Rizzo P, Pass HI, Di Resta I, Powers A, Mutti L, Kast WM and Carbone M. The biological activities of SV 40 T and its possible oncogenic effects in humans. Monaldi Arch Chest Dis 53:193-197, 1998.
  169. Schoenberger SP, Jonges LE, Mooijaart RJD, Hartgers F, Toes REM, Kast WM, Melief CJM and Offringa R: Efficient direct priming of tumor-specific CTL in vivo by an engineered APC. Cancer Res 58:3094-3100, 1998.
  170. Kast WM. New technologies and applications of vaccines. Invest Drugs, 19:25-29, 1998.
  171. Toes REM, van der Voort EIH, Schoenberger SP, and Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R and Melief CJM: Enhancement of tumor-outgrowth through CTL-tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 160:4449-4456, 1998.
  172. Greenstone HL, Nieland JD, De Visser KE, De Bruijn MLH, Kirnbauer R, Roden RBS, Lowy DR, Kast WM and Schiller JT: Chimeric papillomavirus virus-like particles elicit anti-tumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95:1800-1805, 1998. PMID: 9465097
  173. Velders MP, Nieland J, Rudolf MP, Loviscek K, Weijzen S, de Visser KE, Macedo MF, Carbone M, Kast WM: Identification of peptides for cancer immunotherapy, it is still worth the effort. Crit Rev Immunol 18:7-27, 1998.
  174. Klein SC, Van der Burg SH, Boer LH, Melief CJ, Kast WM, de Gast GC and Bast EJ: Targeting CTL against leukemic B cells by bispecific antibody (aCD3 x aCD19) does not distract the T cell from its target. J Immunol 159: 5545-5549, 1997.
  175. Visseren MJW, Van der Burg SH, Van der Voort EIH, Brandt RMP, Schrier PI, Van der Bruggen P, Boon T, Melief CJ Kast WM: Identification of HLA-A2-restricted MAGE-2 CTL epitopes. Int J Cancer 73:125-130, 1997.
  176. Van der Burg SH, Klein MR, Pontesilli O, Holwerda AM, Drijfhout JW, Kast WM, Miedema F and Melief CJM: HIV-1 Reverse Transcriptase-specific cytotoxic T lymphocytes (CTL) against conserved epitopes do not protect against progression to AIDS. J Immunol 159:3648-3654, 1997.
  177. Toes RE, Schoenberger SP, Van der Voort EIH, Kast WM, Hoeben RC, Melief CJM and Offringa R: Activation or frustration of anti-tumor responses by T cell-based immune modulation. Semin Immunol 9:323-327, 1997.
  178. Vierboom MP, Nijman HW, Offringa R, Van der Voort EI, Van Hall T, Van den Broek L, Fleuren GJ, Kenemans P, Kast WM and Melief CJ: Tumor eradication by wild type p53 specific CTL. J Exp Med 186:695-704, 1997.
  179. Kast WM: Basic aspects of vaccines. Invest Drugs 22:41-45, 1997.
  180. Vennegoor CJGM, Nijman HW, Drijfhout JW, Vernie L, Verstraeten RA, Von Mensdorff-Pouilly S, Hilgers J, Verheijen RHM, Kast WM, Melief CJM and Kenemans P: Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett 116:93-101, 1997.
  181. Ressing ME, Offringa R, Toes REM, Ossendorp F, de Jong JH, Brandt RMP, Kast WM, Melief CJM: Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotechnol 2:241-251, 1996.
  182. Van Driel WJ, Ressing ME, Brandt RMP, Toes REM, Fleuren GJ, Trimbos JB, Kast WM and Melief CJM: The current status of therapeutic HPV vaccine. Ann Med 28:471-477, 1996.
  183. Melief CJM, Offringa R, Toes REM and Kast WM: Peptide based cancer vaccines. Curr Opin Immunol 8:651-657, 1996.
  184. Kono K, Ressing ME, Brandt RMP, Melief CJM, Potkul RK, Andersson B, Peterson M, Kast WM and Kiessling R: Decreased expression of signal transducing zeta chain on peripheral T-cells and NK-cells in patients with cervical cancer. Clin Cancer Res 2:1825-1828, 1996.
  185. Ossevoort MA, De Bruijn MLH, Van Veen KJH, Kast WM and Melief CJM: Peptide specificity of alloreactive T lymphocytes directed against a major histocompatibility complex class I disparity. Transpl 62:1485-1491, 1996.
  186. Toes REM, Blom RJJ, Van der Voort EIH, Offringa R, Melief CJM and Kast WM: Protective anti-tumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 56:3782-3787, 1996.
  187. Toes REM, Offringa R, Blom RJJ, Melief CJM and Kast WM: Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93:7855-7860, 1996.
  188. Kast WM, Feltkamp MCW, Ressing ME, Vierboom MPM, Brandt RMP and Melief CJM: Cellular immunity against human papillomavirus associated cervical cancer. Semin Virol 7:117-123, 1996.
  189. Toes REM, Blom RJJ, Offringa R, Kast WM and Melief CJM: Enhanced tumor outgrowth after peptide vaccination: Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 156:3911-3918, 1996.
  190. Van der Burg SH, Visseren MJW, Kast WM and Melief CJM: Immunogenicity of peptides bound to MHC class I molecules is determined by the MHC-peptide complex stability. J Immunol 156:3308-3314, 1996.
  191. Toes REM, Kast WM, Blom RJJ, Bakker SC, Offringa R and Melief CJM: Efficient tumor eradication by adoptively transferred CTL clones in allogeneic hosts. Int J Cancer 66:686-691, 1996.
  192. Ressing ME, Van Driel WJ, Celis E, Sette A, Brandt RMP, Hartman M, Anholts JDH, Schreuder GMT, Ter Harmsel WB, Fleuren GJ, Trimbos BJ, Kast WM and Melief CJM: Occasional memory CTL responses of patients with HPV type 16-positive cervical lesions against an HLA-A*0201-restricted E7-encoded epitope. Cancer Res 56:582-588, 1996.
  193. Zhu X, Tommasino M, Vousden K, Sadovnikava E, Rappuoli R, Crawford L, Kast WM, Melief CJM, Beverley PC and Stauss HJ: Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papillomavirus 16 in H-2d mice. Scand J Immunol 42(5):557-563, 1995.
  194. Ossevoort MA, Feltkamp MCW, Van Veen KJH, Melief CJM and Kast WM: Dendritic cells as carriers for a CTL epitope based vaccine in protection against a HPV type 16 induced tumor. J Immunother 18:86-94, 1995.
  195. Bremers AJA, Van der Burg SH, Kuppen PJK, Kast WM and Melief CJM: The use of Epstein Barr virus transformed B lymphocyte cell lines in a peptide reconstitution assay: Identification of CEA related HLA-*A0301 restricted potential cytotoxic T lymphocyte epitopes. J Immunother 18:77-85, 1995.
  196. Van der Burg SH, Ras E, Drijfhout JW, Benckhuysen WE, Melief CJM and Kast WM: An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells: Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol 44:189-198, 1995.
  197. Mayordomo JI, Zorina T, Storkus WJ, Celluzi C, Falo LD, Melief CJ, IIdstad ST, Kast WM, De Leo A, Lotze MT: Bone marrow-derived DC pulsed with tumor peptides effectively treat established tumors. Nature Med 1: 1297-1302, 1995.
  198. Feltkamp MCW, Vreugdenhil GR, Vierboom MPM, Ras E, Van der Burg SH, Ter Schegget J, Melief CJM, Kast WM: CTL raised against a subdominant epitope offered as a synthetic peptide eradicate HPV type 16-induced tumors. Eur J Immunol 25:2638-2642, 1995.
  199. Toes REM, Feltkamp MCW, Ressing ME, Vierboom MPM, Blom RJJ, Brandt RMP, Hartman M, Offringa R, Melief CJ, and Kast WM: Cellular immunity against DNA tumor viruses. Biochem Soc Trans 23:692-696, 1995.
  200. Feltkamp MCW, Vierboom MPM, Toes REM, Ossendorp F, Ter Schegget J, Melief CJM and Kast WM: Competition inhibition of CTL lysis, a sensitive method to identify candidate CTL epitopes. Immunol Letters 47:1-8, 1995.
  201. Melief CJM and Kast WM: T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 145:167-177, 1995.
  202. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJM, Kast WM: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154:5934-5943, 1995.
  203. Kleijmeer MJ, Ossevoort MA, Van Veen CJH, Van Hellemond JJ, Neefjes JJ, Kast WM, Melief CJM and Geuze HJ: MHC class II compartments and the kinetics of antigen presentation in activated DC. J Immunol 154: 5715-5724, 1995.
  204. Nijman HW, Kleijmeer MJ, Ossevoort MA, Oorschot VM, Vierboom MP, Van de Keur M, Kast WM, Geuze HJ and Melief CJM: Antigen capture and MHC II compartments of freshly human blood DC. J Exp Med 182:163-174, 1995.
  205. Hooijberg E, Sein JJ, Van den Berk PCM, Hart AAM, Van der Valk MA, Kast WM, Melief CJM and Hekman A: Eradication of human B-cell tumors in nude nice with unconjugated CD20 moabs/IL-2. Cancer Res 55:2627-2634, 1995.
  206. D’Amaro J, Houbiers JGA, Drijfhout JW, Brandt RMP, Schipper R, Bouwes Bavinck JN, Melief CJM and Kast WM: A computer program predicting CTL epitopes based on MHC I peptide binding motives. Hum Immunol 43:13-18, 1995.
  207. Drijfhout JW, Brandt RMP, D’Amaro J, Kast WM and Melief CJM: Detailed motifs for peptide binding to HLA-A2 derived from large random sets of peptides using a cellular binding assay. Hum Immunol 43:1-12, 1995.
  208. Visseren MJW, Van Elsas A, Van der Voort EIH, Ressing ME, Kast WM, Schrier PI, Melief CJM: CTL specific for tyrosinase can be induced from healthy donors to lyse melanoma cells. J Immunol 154:3991-3998, 1995.
  209. Toes RE, Offringa R, Blom RJ, Brandt RM, Van der Eb J, Melief CJ and Kast WM: An Ad5 E1B-encoded CTL epitope mediating tumor eradication by CTL clones is down-modulated by activated ras. J Immunol 154:3396-3405, 1995.
  210. Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJM and Schrier PI: Induction and characterization of CTL recognizing a mutant p21ras peptide presented by HLA-A2. Int J Cancer 61:1-8, 1995.
  211. Neisig A, Roelse J, Sijts AJAM, Ossendorp F, Feltkamp MCW, Kast WM, Melief CJM and Neefjes JJ: Major differences in TAP dependent translocation of MHC I presentable peptides. J Immunol 154:1273-1279, 1995.
  212. Van der Burg SH, Klein MR, Van de Velde CJH, Kast WM, Miedema F and Melief CJM: Induction of primary human CTL response against a novel conserved epitope in a sequence of HIV-1 rt. AIDS 9:121-127, 1995.
  213. Grey HM, Ruppert J, Vitiello A, Sidney J, Kast WM, Kubo RT and Sette A: Class I MHC-peptide interactions: Structural requirements and functional implications. Cancer Surveys 22:37-49, 1995.
  214. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJM, Oseroff C, Yuan L, Ruppert J, Sidney J, Del Guercio M-F, Southwood S, Kubo RT, Chesnut RW, Grey HM and Chisari FV: The relationship between class I binding affinity and immunogenicity of CTL epitopes. J Immunol 153:5586-5592, 1994.
  215. Feltkamp MCW, Vierboom MPM, Kast WM and Melief CJM: Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol Immunol 31:1391-1401, 1994.
  216. Sijts AJAM, De Bruijn MLH, Ressing ME, Nieland JD, Mengede EAM, Boog CJP, Ossendorp F, Kast WM and Melief CJM: Identification of an H-2Kb presented Moloney MulV CTL epitope that displays enhanced recognition in H-2Db mutant bm13 mice. J Virol 68:6038-6046, 1994.
  217. Kast WM, Brandt RMP, Sidney J, Drijfhout JW, Kubo RT, Grey HM, Melief CJM and Sette A: The Role of HLA-A motifs in identification of CTL epitopes in HPV type 16 E6 and E7 proteins. J Immunol 152:3904-3912, 1994.
  218. Nijman HW, Van der Burg SH, Vierboom MPM, Houbiers JGA, Kast WM and Melief CJM: P53 a potential target for tumor directed T cells. Immunol Lett 40:171-178, 1994.
  219. Visseren MJW, Koot M, Van der Voort EIH, Gravestein L, Kast WM, Zijlstra M and Melief CJM: Production of IL-2 by EL4 tumors induces natural killer cell and T cell mediated resistance. J Immunother 15:119-128, 1994.
  220. Houbiers JGA, Nijman HW, Van der Burg SH, Drijfhout JW, Kenemans P, Van der Velde CHJ, Brand A, Kast WM and Melief CJM: In-vitro induction of CTL response against wild type or mutant p53 peptides. J Cell Biochem, 17:109, 1993.
  221. Ossevoort MA, Toes REM, De Bruijn MLH, Melief CJM, Figdor CG, Kast WM: MHC expression of DC from mouse spleen isolated by centrifugal elutriation is upregulated during short term culture. Adv Exp Med Biol 329:185-191, 1993.
  222. Melief CJM and Kast WM: Potential immunogenicity of oncogene and tumor suppressor gene products. Curr Opin Immunol 5:709-713, 1993.
  223. Ossevoort MA, Sijts AJAM, Van Veen KJH, Momburg F, Hammerling GJ, Seelig A, Butcher GW, Howard JC, Kast WM and Melief CJM: Differential effect of transporter Tap 2 gene introduction into RMA-S cells on viral antigen processing. Eur J Immunol 23:3082-3088, 1993.
  224. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, De Jongh BM, Drijfhout JW, Ter Schegget J, Melief CJM and Kast WM: Vaccination with cytotoxic T cell epitope-containing peptide protects against a tumor induced by HPV type 16-transformed cells. Eur J Immunol 23:2242-2249, 1993. PMID: 7690326
  225. Houbiers JGA, Nijman HW, Van der Burg SH, Drijfhout JW, Kenemans P, Van de Velde CJH, Brand A, Momburg F, Kast WM and Melief CJM: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53. Eur J Immunol 23:2072-2077, 1993.
  226. Nijman HW, Houbiers JGA, Van der Burg SH, Vierboom MPM, Kenemans P, Kast WM and Melief CJM: Characterization of CTL epitopes of a self protein, p53, and a non-self protein, influenza matrix: relationship between MHC peptide binding affinity / immune responsiveness to peptides. J Immunother 14:121-126, 1993.
  227. Kast WM, Brandt RMP, Drijfhout JW and Melief CJM: HLA-A2.1 restricted candidate CTL epitopes of HPV type 16E6 and E7 proteins identified by using the processing defective human cell line T2. J Immunother 14:115-120, 1993.
  228. Toes REM, Den Haan J, Feltkamp MCW, Blom RJJ, Melief CJM, Claassen E and Kast WM: In vivo detection of fluorescent tumor-specific cytotoxic T cell clones. J Immunol Meth 163:23-32, 1993.
  229. Wykes MN, Shellam GR, McCluskey J, Kast WM, Dallas PB and Price P: Murine cytomegalovirus interacts with MHC class I molecules to establish cellular infection. J Virol 67:4182-4189, 1993.
  230. Nijman HW, Houbiers JGA, Vierboom MPM, Van der Burg SH, Drijfhout JW, Kenemans P, Melief CJM and Kast WM: Identification of peptide sequences that potentially trigger HLA-A2 restricted CTL. Eur J Immunol 23:1215-1219, 1993.
  231. Kast WM, Brandt RMP and Melief CJM: Strict peptide length is not required for the induction of CTL mediated antiviral protection by peptide vaccination. Eur J Immunol 23:1189-1192, 1993.
  232. De Bruijn MLH, Nieland JD, Schumacher TNM, Ploegh HL, Kast WM and Melief CJM: Mechanisms of induction of primary virus specific cytotoxic T lymphocyte responses. Eur J Immunol 22:3013-3020, 1992.
  233. Ossevoort MA, Toes REM, De Bruijn MLH, Melief CJM, Figdor CG and Kast WM: A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation. J Immunol Meth 155:101-111, 1992.
  234. Van Twuyver E, Mooijaart RJD, Ten Berge IJM, Van der Horst AR, Wilmink JM, Kast WM, Melief CJM, De Waal LP: Pretransplantation blood transfusion. N Engl J Med (letter) 326:1027-1028, 1992.
  235. Sijts EJAM, De Bruijn MHL, Nieland JD, Kast WM and Melief CJM: Cytotoxic T Lymphocytes against the antigen processing defective RMA-S tumor cell line. Eur J Immunol 22:1639-1642, 1992.
  236. Melief CJM and Kast WM: Lessons from T cell responses to virus-induced tumors for cancer eradication in general. Cancer Surveys 13:81-99, 1992.
  237. De Bruijn MLH, Schumacher TNM, Nieland JD, Ploegh HL, Kast WM and Melief CJM: Peptide loading of empty MHC molecules on RMA-S cells allows induction of primary CTL responses. Eur J Immunol 21:2963-2970, 1991.
  238. Van Twuyver E, Mooijaart RJD, Ten Berge IJM, Van Der Horst AR, Wilmink JM, Kast WM, Melief CJM, De Waal LP: Pretransplant blood transfusion revisited. N Engl J Med, 325:1210-1213, 1991.
  239. Kast WM, Melief CJ: In vivo efficacy of virus derived peptides and virus-specific CTL. Immunol Lett 30:229-232, 1991.
  240. Melief CJM and Kast WM: T cell immunotherapy of cancer. Res Immunol 142:425-429, 1991.
  241. Kast WM and Melief CJM: Fine peptide specificity of cytotoxic T lymphocytes directed against Adenovirus induced tumors and peptide-MHC binding. Int J Cancer 6:90-94, 1991.
  242. Schumacher TNM, De Bruijn MLH, Vernie LN, Kast WM, Melief CJM, Neefjes JJ and Ploegh HL: Peptide selection by MHC class I molecules. Nature 350:703-706, 1991.
  243. Kast WM, Roux LM, Curren J, Blom HJJ, Voordouw AC, Meloen RH, Kolakovsky D and Melief CJM: Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA 88:2283-2287, 1991.
  244. De Waal LP, Van Twuyver E, Mooijaart RJD, Lardy NM, Kast WM and Melief CJM: Mechanisms of transplantation tolerance. Do anti-idiotypic antibodies play a role? Transpl Proc 23:155-156, 1991.
  245. Van Twuyver E, Mooijaart RJD, Kast WM, Melief CJM and De Waal LP: Different requirements for the regulation of transplantation tolerance induction for allogeneic versus xenogeneic MHC antigens. Hum Immunol 29:220-228, 1990.
  246. Schumacher TNM, Heemels M-T, Neefjes JJ, Kast WM, Melief CJM and Ploegh HL: Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 62:563-567, 1990.
  247. Kast WM, Bluestone JA, Heemskerk MHM, Spaargaren J, Voordouw AC, Ellenhorn JDI and Melief CJM: Treatment with anti-CD3 protects against lethal Sendai virus infection by induction of NK cells. J Immunol 145:2254-2259, 1990.
  248. Van Den Heuvel SJL, Van Laar T, Kast WM, Melief CJM, Zantema A, Van Der Eb AJ: Association between the cellular p53 and the Ad 5E1B-55kD proteins reduces the oncogenicity of Ad transformed cells. EMBO J 9:2621-2629, 1990.
  249. Kast WM: CTL tegen virussen en virus-geïnduceerde tumoren. Analyse 45:128-130, 1990.
  250. Melief CJM and Kast WM: Efficacy of CTL against virus-induced tumors. Cancer Cells 2:116-120, 1990.
  251. Van Twuyver E, Kast WM, Mooijaart RJD, Melief CJM and De Waal LP: Induction of transplantation tolerance by intravenous injection of allogeneic lymphocytes across an H-2 class II mismatch. Different mechanisms operate in tolerization across an H-2 class I versus class II disparity. Eur J Immunol 20:441-444, 1990.
  252. Van Twuyver E, Kast WM, Mooijaart RJD, Melief CJM and De Waal LP: Transfusion induced skin allograft enhancement across an H-2 class I mismatch is caused by a clonal deletion of donor specific cytotoxic T-lymphocyte precursors within the allograft. Transpl Proc 21:1169-1170, 1989.
  253. Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, Van Der Eb AJ and Melief CJM: Eradication of Adenovirus E1-induced tumors by E1A specific cytotoxic T lymphocytes. Cell 59:603-614, 1989.
  254. Van Twuyver E, Kast WM, Mooijaart RJD, Wilmink JM, Melief CJM and De Waal LP: Allograft tolerance induction in mice associated with functional deletion of specific CTL precursors. Transpl 48:844-847, 1989.
  255. Kast WM, Offringa R, Voordouw AC, Van Der Eb AJ and Melief CJM: Efficiënte therapie van Adenovirus geïnduceerde tumoren met cytotoxische T cellen. Ned Tijdschr Geneesk 133:1716, 1989.
  256. Stam NJ, Kast WM, Voordouw AC, Pastoors LB, Van Der Hoeven FA, Melief CJM and Ploegh HL: Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells. J Immunol 142:4113-4117, 1989.
  257. Kast WM, Van Twuyver E, Mooijaart RJD, Verveld M, Kamphuis AGA, Melief CJM and De Waal LP: Mechanism of skin allograft enhancement across an H-2 class I mutant difference. Evidence for involvement of veto cells. Eur J Immunol 18:2105-2108, 1988.
  258. Kast WM, Boog CJP, Roep BO, Voordouw AC and Melief CJM: Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells. J Immunol 140:3186-3193, 1988.
  259. Kast WM, Voordouw AC, Leupers T, Visser JWM and Melief CJM: Thymic immune response gene function in radiation chimeras reconstituted with purified hemopoietic stem cells. Eur J Immunol 17:471-475, 1987.
  260. Cochet M, Kast WM, Kummer AM, Transy C, Melief CJM and Kourilsky P: Alternative splicing in the mouse H-2Kd gene is not necessary for the classical Kd antigen function. Immunogenetics 24:267-274, 1986.
  261. De Waal L, Van Twuyver E and Kast WM. Blood transfusion effect in the mouse. Hum Immunol 17:113, 1986.
  262. Kast WM, Bronkhorst AM, De Waal LP and Melief CJM: Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC-restricted and MHC-regulated, a model for MHC-disease associations. J Exp Med 164:723-738, 1986.
  263. Boog CJP, Kast WM, Timmers HThM, Boes J, De Waal LP and Melief CJM: Abolition of specific immune response defect by immunization with dendritic cells. Nature 318:59-62, 1985.
  264. Kast WM, De Waal LP and Melief CJM: The thymus dictates MHC specificity and immune response phenotype of MHC II restricted T cells but not of MHC I restricted T cells. J Exp Med 160:1752-1766, 1984.
  265. Kast WM, De Waal LP and Melief CJM: The thymus induces maturation of CTLp, dictates differentiation and immune response phenotype of T cells restricted to class II MHC molecules but does not dictate differentiation and immune response phenotype of T cells restricted to class I MHC molecules. Immunobiol 167:127, 1984.
  266. Kast WM, De Waal LP and Melief CJM: Limiting dilution and clonal analysis of Sendai virus-specific cytotoxic T lymphocyte precursors in C57BL/6 mice and a series of H-2Kb mutant mice. Immunobiol 167:77-78, 1984.
  267. Melief CJM, Stukart MJ, De Waal LP, Kast WM and Melvold RW: Specificity and regulation of cytotoxic T-lymphocyte responses analyzed with H-2 mutants. Transpl Proc 15:2086-2089, 1983.
  268. De Waal LP, Kast WM, Melvold RW and Melief CJM: Regulation of the cytotoxic T-lymphocyte response against Sendai virus analyzed with H-2 mutants. J Immunol 130:1090-1096, 1983.
  269. Wever R, Kast WM, Kasinoedin JH and Boelens R: The peroxidation of thiocyanate catalyzed by myeloperoxidase and lactoperoxidase. Biochem Biophys Acta 709:212-219, 1982.